What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question

V. Basile, S. Puglisi*, B. Altieri, L. Canu, R. Libe, F. Ceccato, F. Beuschlein, M. Quinkler, A. Calabrese, P. Perotti, P. Berchialla, U. Dischinger, F. Megerle, E. Baudin, I. Bourdeau, A. Lacroix, P. Loli, A. Berruti, D. Kastelan, H.R. HaakM. Fassnacht, M. Terzolo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question'. Together they form a unique fingerprint.

Keyphrases

INIS

Mathematics

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science